![]() |
市場調査レポート
商品コード
1451893
経口抗生物質市場レポート:クラス別、用途、薬剤由来、活性領域、薬剤タイプ、地域、2024~2032年Oral Antibiotics Market Report by Class, Application (Community-acquired Respiratory Tract Infections, Urinary Tract Infections, Dental and Others), Drug Origin, Spectrum of Activity, Drug Type, and Region 2024-2032 |
||||||
カスタマイズ可能
|
経口抗生物質市場レポート:クラス別、用途、薬剤由来、活性領域、薬剤タイプ、地域、2024~2032年 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2~3営業日
|
経口抗生物質の世界市場規模は2023年に204億140万米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて3.32%の成長率(CAGR)を示し、2032年までに276億1,220万米ドルに達すると予測しています。感染症の蔓延、高齢者人口の増加、薬剤耐性菌に対する効果的な治療に対する需要の高まり、個別化医療とゲノミクスの動向の高まりなどが、市場を牽引する主要要因となっています。
経口抗生物質は、主に細菌の増殖を抑制したり、体内から細菌を除去するために処方される医薬品です。通常、口から服用し、幅広い医療用途で利用されています。経口抗生物質によって治療される感染症の種類は様々で、皮膚、耳、喉、尿路感染症などの一般的な疾患から、ある種の肺炎のような複雑な疾患まで含まれます。これらの抗生物質は異なるクラスに分類され、それぞれ作用機序が異なります。よく処方されるクラスには、ペニシリン系、フルオロキノロン系、テトラサイクリン系、マクロライド系などがあります。それぞれのクラスは、異なるタイプの細菌を標的とし、特定の細菌感染症により効果的です。例えば、ペニシリン系は溶連菌感染症に広く使用され、フルオロキノロン系は特定のグラム陰性菌に対抗するために選択されます。その結果、経口抗生物質は現代医療の重要な要素であり、多くの細菌感染症の治療を成功させるために医療専門家によって広く処方されています。
感染症の有病率の増加と、これらの症状に対する利用可能な治療オプションに関する一般市民の意識の高まりが、市場の成長を支える主要要因となっています。さらに、このような感染症を発症しやすい高齢者人口の拡大も、市場の成長を後押しする主要要因です。さらに、抗生物質の普及を促し、抗生物質耐性の出現を遅らせ、これらの薬剤の効果を長持ちさせることを目的とした抗生物質スチュワードシップ・プログラムが増加しています。これに伴い、抗生物質耐性の問題が深刻化しているため、研究者や製薬会社は既存の抗生物質クラスを変更し、多剤耐性菌に対応できる新しい抗生物質を開発せざるを得なくなり、製品採用率が加速しています。さらに、大手製薬会社や研究機関は、細菌の耐性パターンを予測し、薬剤と細菌の相互作用を理解し、新規抗生物質の発見を迅速化するために、創薬プロセスにおいて人工知能(AI)や機械学習(ML)を活用しています。これに伴い、個別化医療とゲノミクスの台頭が、治療効果を高め副作用を最小限に抑えるために遺伝的体質などの要因を考慮して個々の患者に合わせた抗生物質治療を行うことを含み、市場の成長を促進しています。薬剤耐性菌に対する効果的な治療に対する需要の高まり、医療インフラの改善、新規経口抗生物質の継続的な発売、研究開発(R&D)活動への多額の投資などのその他の要因も、今後数年間の市場成長を促進すると予想されます。
The global oral antibiotics market size reached US$ 20,401.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 27,612.2 Million by 2032, exhibiting a growth rate (CAGR) of 3.32% during 2024-2032. The increasing prevalence of infectious diseases, expanding geriatric population, escalating demand for effective treatments against drug-resistant bacteria, and the growing trend of personalized medicine and genomics represent some of the key factors driving the market.
Oral antibiotics are pharmaceutical agents primarily prescribed to inhibit bacterial growth or eliminate bacteria from the body. They are usually taken by mouth and are utilized across a wide range of medical applications. The types of infections treated by oral antibiotics vary and include common ailments such as skin, ear, throat, and urinary tract infections and more complex conditions like certain types of pneumonia. These antibiotics are categorized into different classes, each with a distinct mechanism of action. Some commonly prescribed classes include penicillins, fluoroquinolones, tetracyclines, and macrolides. Each class targets different types of bacteria and is more effective for specific bacterial infections. For instance, penicillins are widely used for streptococcal infections, while fluoroquinolones may be chosen to combat certain gram-negative bacteria. As a result, oral antibiotics are a key element of modern healthcare and are widely prescribed by healthcare professionals to enable the successful treatment of numerous bacterial infections.
The increasing prevalence of infectious diseases and the rising public awareness about the available treatment options for these conditions represent the primary factors supporting market growth. Moreover, the expanding geriatric population that is more susceptible to developing such infections is another major factor fueling the market growth. In addition, there has been a rise in antibiotic stewardship programs aimed at encouraging the widespread use of antibiotics, slowing down the emergence of antibiotic resistance, and ensuring the prolonged effectiveness of these drugs. Along with this, the growing issue of antibiotic resistance has compelled researchers and pharmaceutical companies to modify existing classes and develop new antibiotics capable of treating multi-drug resistant bacteria, thereby accelerating the product adoption rate. Furthermore, the leading pharmaceutical companies and research institutes are leveraging artificial intelligence (AI) and machine learning (ML) in the drug discovery process to predict bacterial resistance patterns, understand drug-bacteria interactions, and expedite the discovery of novel antibiotics. In line with this, the emergence of personalized medicine and genomics, which involves tailoring antibiotic treatment to individual patients by considering factors such as their genetic makeup to enhance treatment effectiveness and minimize side effects, has catalyzed market growth. Other factors, including escalating demand for effective treatments against drug-resistant bacteria, improving healthcare infrastructure, the continual launch of novel oral antibiotics, and heavy investments in research and development (R&D) activities, are also anticipated to propel the market growth in the coming years.
IMARC Group provides an analysis of the key trends in each segment of the global oral antibiotics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on the class, application, drug origin, spectrum of activity, and drug type.
Beta Lactam and Beta Lactamase Inhibitors
Penicillin
Cephalosporin
Others
Quinolone
Macrolide
Others
The report has provided a detailed breakup and analysis of the oral antibiotics market based on the class. This includes beta lactam and beta lactamase inhibitors (penicillin, cephalosporin, and others), quinolone, macrolide, and others. According to the report, beta lactam and beta lactamase inhibitors represented the largest segment.
Community-acquired Respiratory Tract Infections (CARTIs)
Upper Respiratory Tract Infections (URTI)
Lower Respiratory Tract Infections (LRTIs)
Urinary Tract Infections (UTIs)
Dental
Combination
Monotherapies
Others
A detailed breakup and analysis of the oral antibiotics market based on the application has also been provided in the report. This includes community-acquired respiratory tract infections (upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs)), urinary tract infections (UTIs), dental (combination and monotherapies), and others. According to the report, urinary tract infections (UTIs) accounted for the largest market share.
Natural
Semisynthetic
Synthetic
The report has provided a detailed breakup and analysis of the oral antibiotics market based on the drug origin. This includes natural, semisynthetic, and synthetic. According to the report, synthetic represented the largest segment.
Broad-spectrum Antibiotic
Narrow Spectrum Antibiotic
A detailed breakup and analysis of the oral antibiotics market based on the spectrum of activity has also been provided in the report. This includes broad-spectrum antibiotic and narrow spectrum antibiotic.
Branded
Generics
The report has provided a detailed breakup and analysis of the oral antibiotics market based on the drug type. This includes branded and generics.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia-Pacific was the largest market for oral antibiotics. Some of the factors driving the Asia-Pacific oral antibiotics market included its aging population, growing burden of infectious diseases, high healthcare expenditure, the presence of various key players, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global oral antibiotics market. Detailed profiles of all major companies have been provided. Some of the companies covered include Bayer AG, Cipla Inc., Gilead Sciences Inc., Janssen Inc. (Johnson & Johnson Services, Inc.), Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.